SCHEMBL4350554

SCHEMBL4350554

COc1ccc(C(C)=CC=C2SC(N3CCOCC3)=NC2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.52
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
NPC1 O15118 3/20 0.52
MAPT P10636 11/20 0.51
ALDH1A1 P00352 9/20 0.51
SMN1; SMN2 Q16637 5/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
HCRTR1 O43613 1/20 0.51
GAA P10253 2/20 0.47
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.46
LMNA P02545 2/20 0.44
PSMD14 O00487 1/20 0.44
RECQL P46063 1/20 0.43
POLB P06746 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350552 1.00 RAB9A (0.52) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4346313 0.88 SMN1; SMN2 (0.64) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4346315 0.88 SMN1; SMN2 (0.64) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4364867 0.85 MAPT (0.53) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4364864 0.85 MAPT (0.53) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4358503 0.84 MAPT (0.50) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4358508 0.84 MAPT (0.50) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4359787 0.80 MEN1 (0.78) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4359783 0.80 MEN1 (0.78) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4357379 0.77 MAPT (0.50) RAB9AMEN1KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 RAB9A 3151/4885MEN1 1725/4885KMT2A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.